Since the 1960s, the incidence of allergic disease in Western countries has progressively increased. There are a number of theories as to what is causing this trend: the Hygiene Hypothosis and microbiota imbalances being the two most recognised. We filmed Manuel Llobet, CEO of Allergy Therapeutics (LON:AGY), discussing the causes behind the rise in Allergies.
Allergy Therapeutics Plc (LON:AGY) is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.